Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-1976 mimic is a synthetic microRNA designed to replicate the biological activity of endogenous miR-1976. It functions by binding to the mRNA of La Ribonucleoprotein Domain Family Member 6 (LARP6), a protein that facilitates the translation of type I collagen. By downregulating LARP6, the miR-1976 mimic reduces the production of type I procollagen and mature collagen fibrils in vascular smooth muscle cells. This pathway is particularly relevant in the context of atherosclerosis, where insulin-like growth factor-1 (IGF1) has been shown to downregulate miR-1976, thereby promoting collagen-mediated plaque stabilization. The mimic serves as a potential therapeutic tool to modulate collagen content and plaque stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-1976 mimic.